ライフサイエンスコーパス: FDG-PET

1 FDG-PET radiomics features were selected by Lasso-Cox re

2 FDG-PET/CT in patients with SAB seems to improve surviva

3 MRI scans coregistered with interictal (18) FDG-PET.

4 (18)FDG-PET may enhance the diagnostic efficacy in patients

5 (18)FDG-PET/CT can visualize both inflammation and malignanc

6 Clinic of Samsung Medical Center with an (18)FDG-PET/CT order code were extracted.

7 The sensitivity of (18)FDG-PET/CT was 63.6%.

8 emission tomography/computed tomography ((18)FDG-PET/CT) in the differential diagnosis of pericardial

9 18F-FDG PET/CT showed bilateral hypermetabolic adrenal masse

10 ccuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting residual

11 ccuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease after neoadj

12 d by [18F]-2-fluoro-d-2-deoxy-d-glucose (18F-FDG) PET/CT.

13 18F-FDG-PET/CT accuracy was determined in the subgroups of p

14 een inflammatory infiltrate patterns and 18F-FDG-PET/CT uptake were investigated in an exploratory ad

15 monstrate that pretreatment TRL misleads 18F-FDG-PET/CT during lymph node staging in gynecological ma

16 h node of TRL-positive patients misleads 18F-FDG-PET/CT for detecting nodal metastasis.

17 Use of 18F-FDG-PET/CT at the initial presentation of patients with

18 sitive and negative predictive values of 18F-FDG-PET/CT focal uptake were 93%, 90%, 89%, and 94%, res

19 ere is limited evidence regarding use of 18F-FDG-PET/CT for the diagnosis of native valve endocarditi

20 s (TRL) on the diagnostic performance of 18F-FDG-PET/CT in detecting pelvic and paraaortic lymph node

21 o present with suspected NVE, the use of 18F-FDG-PET/CT is less accurate and could only be considered

22 gations, we show that the false-positive 18F-FDG-PET/CT result for detecting nodal metastasis can be

23 emission tomography-computed tomography (18F-FDG-PET/CT) can be influenced by the increased glycolyti

24 emission tomography/computed tomography (18F-FDG-PET/CT) has emerged as a useful diagnostic tool for

25 ed in vivo glucose utilization measured by 2-FDG PET would be masked to the potentially substantial r

26 ous caveats for this and related roles for 2-FDG PET.

27 Given the widespread use of 2-FDG PET to infer glucose metabolism, appreciating the po

28 Given the widespread use of 2-FDG PET to infer glucose metabolism, it is relevant to a

29 work is not to deny the clinical value of 2-FDG PET; it is a reminder that when one extends the use

30 Even when the readout for the 2-FDG PET study is only an SUV parameter, variability in L

31 tification of glucose metabolic rates with 2-FDG PET, a method that permits the noninvasive assessmen

32 We investigated the benefit of adding FDG-PET/CT in the workup of patients with SAB.

33 tion chemotherapy with whole-body DW MRI and FDG PET/MRI (alpha = 0.88).

34 therapy response with whole-body DW MRI and FDG PET/MRI in children and young adults.

35 ed agreements between whole-body DW MRI- and FDG PET/MRI-based response classifications with Krippend

36 s who were untreated showed no change in any FDG PET or cardiac MRI parameter.

37 o underwent baseline and response assessment FDG PET-CT between August 2008 and May 2017 were include

38 Treatment was directed by FDG-PET/CT findings.

39 and significantly reduced glucose uptake by FDG-PET live animal imaging.

40 Conclusions FDG PET and cardiac MRI can help facilitate the diagnosi

41 the studies showed metastases, with diverse FDG PET findings throughout the whole body.

42 ive who underwent autopsy and for whom (18)F-FDG PET (30 AD, 6 MCI, 2 cognitively normal) and amyloid

43 antly higher with immuno-PET than with (18)F-FDG PET (P = 0.009).

44 ted by principle-components analysis); (18)F-FDG PET (pattern expression score of a previously define

45 mini-mental state examination score); (18)F-FDG PET + amyloid PET; amyloid PET + nonimaging; (18)F-F

46 DG PET + nonimaging; and amyloid PET + (18)F-FDG PET + nonimaging.

47 amyloid PET; amyloid PET + nonimaging; (18)F-FDG PET + nonimaging; and amyloid PET + (18)F-FDG PET +

48 confidence interval [CI]: 0.72, 0.83); (18)F-FDG PET alone, 0.97 (95% CI: 0.97, 0.98); (18)F-FDG PET/

49 o subregions (i.e., habitats) based on (18)F-FDG PET and contrast CT imaging.

50 The combination of (18)F-FDG PET and CT information improved overall classificati

51 Whole-body (18)F-FDG PET and CT scans did not show neoplasia.

52 f simultaneously obtained quantitative (18)F-FDG PET and diffusion-weighted MRI datasets for predicti

53 Therefore, combining (18)F-FDG PET and MRI data may enable more reliable treatment

54 c potential of simultaneously acquired (18)F-FDG PET and MRI data sets for therapy response assessmen

55 templating all subjects with available (18)F-FDG PET and neuropathology information (n = 38), PES of

56 izing lesion dissemination in baseline (18)F-FDG PET and tested whether combining them with baseline

57 Patients underwent CT and (18)F-FDG PET at baseline and after 4 cycles (the first evalua

58 pproach was established and tested for (18)F-FDG PET brain imaging.

59 Conclusion: FMRI and (18)F-FDG PET capture partly different aspects of network inte

60 (18)F-FDG PET could differentiate G1 and G2 tumors into low- a

61 bjective was to evaluate the impact of (18)F-FDG PET CT on the management of urachal adenocarcinoma (

62 eatures before a radiomics analysis of (18)F-FDG PET data and to identify those feature extraction an

63 I, 19%-36%) of patients, an additional (18)F-FDG PET exam was requested, because BS provided insuffic

64 Methods: Baseline ceCT, BS, and (18)F-FDG PET for all patients included in the IMPACT-MBC stud

65 showed higher sensitivity than MRI or (18)F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, res

66 Metabolic imaging with (18)F-FDG PET has extensive utility in the staging, assessment

67 ty of radiomic features extracted from (18)F-FDG PET images of cervical tumors.

68 ontrast-enhanced high-resolution CT or (18)F-FDG PET images were used for coregistration.

69 s developed to measure tumor volume in (18)F-FDG PET images.

70 udy evaluating the prognostic value of (18)F-FDG PET imaging and compared it with histologic grading.

71 ts (n = 13) followed by dual MEMRI and (18)F-FDG PET imaging at 10-12 weeks.

72 sess the long-term prognostic value of (18)F-FDG PET imaging for risk stratification of NENs and comp

73 of reduced scan duration in oncologic (18)F-FDG PET imaging on quantitative and subjective imaging p

74 (18)F-FDG PET imaging shows these changes are accompanied by a

75 In assessing response to therapy, (18)F-FDG PET imaging was performed at baseline and 4 d after

76 ws inflammatory leukocyte signal using (18)F-FDG PET imaging.

77 ifficult in some patients referred for (18)F-FDG PET imaging.

78 also changed management compared with (18)F-FDG PET in 1 patient (1%; 95% CI, 0%-5%).

79 somewhat higher sensitivity than CT or (18)F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respe

80 immune encephalitis and for the use of (18)F-FDG PET in such a context.

81 udy did not support the routine use of (18)F-FDG PET in the general population of NSCLC patients trea

82 s in metastatic breast cancer (MBC) by (18)F-FDG PET instead of (99m)Tc bone scintigraphy (BS) suppor

83 Interim (18)F-FDG PET is also used for relapse-treatment adaptation; h

84 Conclusion: (18)F-FDG PET is useful for risk stratification of all NEN gra

85 ly assessment of treatment response by (18)F-FDG PET may trigger treatment modification.

86 (18)F-FDG PET measurement of tumor volume holds promise but is

87 Conclusion: (18)F-FDG PET metabolic volume response predicts survival in p

88 he independent validation dataset, the (18)F-FDG PET model yielded a significantly higher predictive

89 Additional bone lesions on (18)F-FDG PET plus ceCT compared with BS plus ceCT led to chan

90 iplinary expert panel, based on either (18)F-FDG PET plus ceCT or BS plus ceCT.

91 ons based on bone lesion assessment by (18)F-FDG PET plus contrast-enhanced CT (ceCT) or BS plus ceCT

92 s of CT-based criteria with respect to (18)F-FDG PET response criteria in non-small cell lung cancer

93 ated with a shorter OS than a negative (18)F-FDG PET scan (hazard ratio: 3.8; 95% CI: 2.4-5.9; P < 0.

94 whole cohort revealed that a positive (18)F-FDG PET scan was associated with a shorter OS than a neg

95 and G2 patients (n = 140), a positive (18)F-FDG PET scan was the only identifier of high risk for de

96 (18)F-FDG PET scans were acquired at 3 and 7 d after TAC, unde

97 (18)F-fluoroestradiol PET and (18)F-FDG PET scans were performed at baseline, week 2, and we

98 On the basis of these data, (18)F-FDG PET should be considered a primary imaging modality

99 Brain (18)F-FDG PET showed diffuse cortical hypometabolism associate

100 In patients with PNS, (18)F-FDG PET shows both abnormality along the course of the i

101 r risk stratification of NEN patients, (18)F-FDG PET status should be considered.

102 ted to optimize the reproducibility of (18)F-FDG PET SUV thresholds, SUV(peak) metrics, and preclinic

103 ILC) demonstrates lower conspicuity on (18)F-FDG PET than the more common invasive ductal carcinoma.

104 develop and optimize image metrics for (18)F-FDG PET to assess response to combination docetaxel and

105 elated response criteria (irRC) and on (18)F-FDG PET using PERCIST and immunotherapy-modified PERCIST

106 lysis of newly diagnosed MBC patients, (18)F-FDG PET versus BS to assess bone lesions resulted in cli

107 Results: In 9 of the 15 patients, (18)F-FDG PET was negative in the presence of viable disease.

108 l lesion sensitivity of immuno-PET and (18)F-FDG PET were 94.7% (1,116/1,178) and 89.6% (1,056/1,178)

109 that 2 radiomic features derived from (18)F-FDG PET were independently associated with local control

110 SSTR-based imaging (but more likely on (18)F-FDG PET) than are well-differentiated NENs, but these da

111 breast parenchymal uptake (BPU) (from (18)F-FDG PET), mean apparent diffusion coefficient (from diff

112 ts (39% by ceCT, 26% by BS, and 87% by (18)F-FDG PET).

113 Conclusion: (18)F-FDG PET, amyloid PET, and nonimaging variables represent

114 tion accuracy was reached by combining (18)F-FDG PET, amyloid PET, and nonimaging variables.

115 Amyloid PET, (18)F-FDG PET, and CSF test combinations may add accuracy to c

116 le studies suggested that amyloid PET, (18)F-FDG PET, and CSF test combinations may add accuracy to c

117 ypical clinical settings, amyloid PET, (18)F-FDG PET, and MRI were highly sensitive for neuropatholog

118 the predictive values of amyloid PET, (18)F-FDG PET, and nonimaging predictors (alone and in combina

119 In multivariate analysis, (18)F-FDG PET, G3 tumor, >=2 liver metastases, and >=2 prior t

120 pendent prognostic factors for OS, and (18)F-FDG PET, G3 tumor, and >=3 liver metastases were indepen

121 aging (MI), championed by radiolabeled (18)F-FDG PET, has expanded the information content derived fr

122 In contrast to (18)F-FDG PET, immuno-PET disclosed brain metastases.

123 These results were confirmed by (18)F-FDG PET, revealing the least amount of viable tumor tiss

124 sion-weighted early-phase acquisition ((18)F-FDG PET-equivalent), a single scan potentially contains

125 resulting in an additional request for (18)F-FDG PET.

126 ancer, compared with CT, bone MRI, and (18)F-FDG PET.

127 higher specificity for malignancy than (18)F-FDG PET.

128 a simultaneous resting-state fMRI and (18)F-FDG PET.

129 18)F-FLT PET/CT was lower than that of (18)F-FDG PET/CT (HDV, 69% [95% CI, 41-89] vs. 94% [95% CI, 70

130 8)F-FLT PET/CT was higher than that of (18)F-FDG PET/CT (HDV, 96% [95% CI, 87-100] vs. 71% [95% CI, 5

131 The value of interim (18)F-FDG PET/CT (iPET)-guided treatment decisions in patients

132 y of malignancy increased from 67% for (18)F-FDG PET/CT alone to 100% when both tracers were positive

133 ved the diagnostic value compared with (18)F-FDG PET/CT alone.

134 ive tumor volume (WB-MATV) measured by (18)F-FDG PET/CT and circulating cell-free DNA (cfDNA) have be

135 e purpose of this study was to compare (18)F-FDG PET/CT and CT performance in guiding percutaneous bi

136 Conclusion: Qualitative evaluation of (18)F-FDG PET/CT and HRCT perform similarly for the diagnosis

137 lar to previously published values for (18)F-FDG PET/CT and MRI, supporting the use of (18)F-FDG PET/

138 sis provides an alternative to dynamic (18)F-FDG PET/CT and Patlak analysis, allowing the assessment

139 association between tumor response on (18)F-FDG PET/CT and prognosis in patients with metastatic mal

140 stat) correlations suggest that static (18)F-FDG PET/CT and SUR(stat) analysis provides an alternativ

141 with definite left-sided IE who had an (18)F-FDG PET/CT and were followed-up for 1 year.

142 ble BAT radiomic features derived from (18)F-FDG PET/CT appear to provide information regarding BAT a

143 (18)F-FDG PET/CT appears to have a limited role in the respons

144 c tumor volume (TMTV), calculated from (18)F-FDG PET/CT baseline studies, is a prognostic factor in d

145 dy was to examine whether staging with (18)F-FDG PET/CT better predicts survival in patients with rec

146 e change in total-lesion glycolysis on (18)F-FDG PET/CT between baseline and 3-mo follow-up.

147 lizumab and had baseline and follow-up (18)F-FDG PET/CT data were analyzed.

148 (18)F-FDG PET/CT demonstrates value for systemic staging of ma

149 (18)F-FDG PET/CT detected previously unidentified metastases i

150 age of euro 6.26 ($7.08) RAI costs per (18)F-FDG PET/CT exam.

151 Methods: In total, 144 whole-body (18)F-FDG PET/CT examinations were acquired, with a respirator

152 End-of-treatment (EOT) (18)F-FDG PET/CT findings are variable among patients with neg

153 ween different clinical phenotypes and (18)F-FDG PET/CT findings was investigated.

154 (AUCs) for determining hypermetabolic (18)F-FDG PET/CT foci that were suspicious for cancer versus n

155 riod, 10,124 unique patients underwent (18)F-FDG PET/CT for breast cancer at our institution.

156 8)F-FES PET/CT compared favorably with (18)F-FDG PET/CT for detection of metastases in patients with

157 Here, we explore the value of (18)F-FDG PET/CT for guidance of patient management.

158 assessed the diagnostic performance of (18)F-FDG PET/CT for IE and its subtypes.

159 ng both sensitivity and specificity of (18)F-FDG PET/CT for IE.

160 oing role of the more widely available (18)F-FDG PET/CT for response assessment is being recognized t

161 evaluate the diagnostic performance of (18)F-FDG PET/CT for the detection of posttransplantation lymp

162 alue, and negative predictive value of (18)F-FDG PET/CT for the detection of PTLD in children with a

163 ce of high-resolution CT (HRCT) versus (18)F-FDG PET/CT for the diagnosis of pulmonary lymphangitic c

164 Conclusion: (18)F-FDG PET/CT had good specificity and positive predictive

165 Conclusions (18)F-FDG PET/CT had high specificity for all IE subtypes; how

166 Conclusion: (18)F-FDG PET/CT has clinical utility in patients with UrC-ADC

167 a suggest that functional imaging with (18)F-FDG PET/CT has unique merits over anatomic imaging and c

168 In 7 of 39 patients (18%), (18)F-FDG PET/CT identified previously unsuspected distant met

169 Conclusion: Whole-body (18)F-FDG PET/CT identifies the extent of LVAD infection and p

170 atients with lymphoma was segmented on (18)F-FDG PET/CT images (acquired between 2005 and 2011) by a

171 patients with advanced-stage DLCBL and (18)F-FDG PET/CT images available for review were selected.

172 classify uptake patterns of whole-body (18)F-FDG PET/CT images in patients with lung cancer and lymph

173 (18)F-FDG PET/CT images were reviewed to qualitatively evaluat

174 Results: Twenty-seven patients had (18)F-FDG PET/CT imaging at baseline and after at least 4 cycl

175 ted for uniformity in conjunction with (18)F-FDG PET/CT imaging of mini image-quality phantoms design

176 7 patients with baseline and follow-up (18)F-FDG PET/CT imaging were retrospectively analyzed.

177 l cancer underwent baseline and repeat (18)F-FDG PET/CT imaging within 7 d.

178 nal, device-based system for oncologic (18)F-FDG PET/CT imaging.

179 )F-FLT PET/CT adds diagnostic value to (18)F-FDG PET/CT in patients with suspected relapse.

180 , FAPI PET/CT provides advantages over (18)F-FDG PET/CT in several tumor entities for initial staging

181 e an overview of the current status of (18)F-FDG PET/CT in the monitoring of tumoral and systemic imm

182 for either replacing or complementing (18)F-FDG PET/CT in the selection and monitoring of immunother

183 nse, systematic analyses on the use of (18)F-FDG PET/CT in this setting are mostly lacking.

184 e suggest adding (18)F-FLT PET/CT when (18)F-FDG PET/CT is inconclusive or positive within the previo

185 The specificity of both CT and (18)F-FDG PET/CT is low because of radiation-induced changes.

186 Although (18)F-FDG PET/CT is widely available and is increasingly being

187 FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); (18)F-FDG PET/CT maximum intensity projection (MIP), 0.98 (95%

188 Conclusion: Serial (18)F-FDG PET/CT might be a useful tool for detecting tumor re

189 (18)F-FDG PET/CT might be able to detect local tumor recurrenc

190 (MIP), 0.98 (95% CI: 0.98, 0.99); and (18)F-FDG PET/CT MIP atlas, 0.99 (95% CI: 0.98, 1.00).

191 etermine the impact of findings on EOT (18)F-FDG PET/CT on tuberculosis relapse in patients treated w

192 of asymptomatic patients who underwent (18)F-FDG PET/CT or (131)I SPECT/CT for standard oncologic ind

193 were simultaneously scanned by dynamic (18)F-FDG PET/CT over 60 min, and quantified images were compa

194 Seven of 14 patients with ILC had (18)F-FDG PET/CT performed within 5 wk of the research (18)F-F

195 f PLC, with both being outperformed by (18)F-FDG PET/CT quantitative parameters.

196 (18)F-FDG PET/CT radiomic features are synergistic to visual a

197 s to develop and evaluate a prognostic (18)F-FDG PET/CT radiomic signature in early-stage non-small c

198 Results: Ninety-eight (3.7%) of 2,643 (18)F-FDG PET/CT reports contained an RAI.

199 Conclusion: RAIs in (18)F-FDG PET/CT reports in a European tertiary-care academic

200 additional imaging (RAIs) in clinical (18)F-FDG PET/CT reports.

201 Conclusion: A negative EOT (18)F-FDG PET/CT result is protective against tuberculosis rel

202 Conclusion: (18)F-FDG PET/CT revealed previously unsuspected distant metas

203 EPAR I and II studies who underwent an (18)F-FDG PET/CT scan at baseline, a posttreatment (166)Ho SPE

204 ent (166)Ho SPECT/CT scan, and another (18)F-FDG PET/CT scan at the 3-mo follow-up were included for

205 en lymphoma disease) underwent staging (18)F-FDG PET/CT scan.

206 Methods: Five (18)F-FDG PET/CT scanners from 4 institutions (2 in a National

207 Two of 5 interim (18)F-FDG PET/CT scans and 3 of 9 end-of-treatment (18)F-FDG P

208 recipients who underwent a total of 32 (18)F-FDG PET/CT scans due to clinical suspicion of PTLD withi

209 udy were to assess the value of serial (18)F-FDG PET/CT scans for detecting local recurrence in patie

210 rrying patients received 85 whole-body (18)F-FDG PET/CT scans for the work-up of device infection.

211 Methods: Baseline (18)F-FDG PET/CT scans of 301 DLBCL patients from the REMARC t

212 tribution were calculated from dynamic (18)F-FDG PET/CT scans using the Patlak analysis.

213 T/CT scans and 3 of 9 end-of-treatment (18)F-FDG PET/CT scans were false-positive.

214 Twenty-one response assessment (18)F-FDG PET/CT scans were reevaluated according to the Lugan

215 Methods: One hundred forty baseline (18)F-FDG PET/CT scans were selected from U.K. and Dutch studi

216 for gynecologic oncology reviewed all (18)F-FDG PET/CT scans.

217 or these 7 patients, the (18)F-FES and (18)F-FDG PET/CT studies were analyzed to determine the total

218 ance over time, related to advances in (18)F-FDG PET/CT techniques.

219 duced by ICIs may limit the ability of (18)F-FDG PET/CT to assess tumor response, systematic analyses

220 ied with both (68)Ga-DOTA-Siglec-9 and (18)F-FDG PET/CT to determine the ability of the new tracer to

221 A diagnostic-driven approach using (18)F-FDG PET/CT to determine treatment duration in high-risk

222 Our objective was to use (18)F-FDG PET/CT to identify a high-risk subgroup requiring th

223 udy in the literature has ever applied (18)F-FDG PET/CT to investigate alterations in brain glucose m

224 Conclusion: (18)F-FDG PET/CT was able to identify predictors of survival i

225 Although an abnormal finding on (18)F-FDG PET/CT was added to the 2015 guidelines of the Europ

226 Repeat (18)F-FDG PET/CT was done in patients who relapsed.

227 ecificity between (18)F-FLT PET/CT and (18)F-FDG PET/CT was higher after cRT than after SBRT.

228 Adding (18)F-FLT PET/CT when (18)F-FDG PET/CT was positive or inconclusive improved the dia

229 Qualitative (18)F-FDG PET/CT was unable to detect TRG3-4 in 15% of patient

230 r imaging probes that might complement (18)F-FDG PET/CT will be discussed.

231 ission tomography/computed tomography ((18)F-FDG PET/CT) has recently emerged as another IE imaging m

232 ission tomography-computed tomography ((18)F-FDG PET/CT) in a large cohort of chemorefractory metasta

233 ission Tomography/Computed Tomography ((18)F-FDG PET/CT).

234 PET alone, 0.97 (95% CI: 0.97, 0.98); (18)F-FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); (18)F-FDG PET/CT

235 on (18)F-FDG PET/CT, Mayo stage after (18)F-FDG PET/CT, and change in patient management were determ

236 tients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete peripheral blood sampling at ba

237 Clinical response evaluations included (18)F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasou

238 e primary malignancy and metastases on (18)F-FDG PET/CT, Mayo stage after (18)F-FDG PET/CT, and chang

239 ts: Of 21 patients with UrC-ADC before (18)F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV

240 Mayo stage before (18)F-FDG PET/CT, rate of detection of the primary malignancy

241 etabolism in the brain, as evaluated by(18)F-FDG PET/CT, seems to correlate with the severe CDCS phen

242 acers in the future, we recommend that (18)F-FDG PET/CT, which represents the host-pathogen immune re

243 ed 341 patients, of whom 216 underwent (18)F-FDG PET/CT-guided biopsy and 125 underwent CT-guided bio

244 patients diagnosed with lymphoma using (18)F-FDG PET/CT.

245 variables and metabolic parameters by (18)F-FDG PET/CT.

246 the esophagus with an initial staging (18)F-FDG PET/CT.

247 detected more metastatic lesions than (18)F-FDG PET/CT.

248 herosclerotic mice with (68)Ga-FOL and (18)F-FDG PET/CT.

249 prospectively recruited to undergo EOT (18)F-FDG PET/CT.

250 The patients then underwent brain (18)F-FDG PET/CT.

251 Our objective was to define an (18)F-FDG PET/MR enterography index as a hybrid surrogate mark

252 irmed STS of the extremities underwent (18)F-FDG PET/MRI before and after ILP with melphalan and tumo

253 sts were used to assess differences in (18)F-FDG PET/MRI biomarkers between patients with benign and

254 ere are differences in multiparametric (18)F-FDG PET/MRI biomarkers of contralateral healthy breast t

255 lusion: Differences in multiparametric (18)F-FDG PET/MRI biomarkers, obtained from contralateral tumo

256 70 +/- 10 kg) underwent a test-retest (18)F-FDG PET/MRI examination of the brain (n = 20).

257 70 +/- 10 kg) underwent a test-retest (18)F-FDG PET/MRI examination of the brain.

258 PET/CT and MRI, supporting the use of (18)F-FDG PET/MRI for quantitative oncologic treatment respons

259 f the evaluated SUV and ADC metrics on (18)F-FDG PET/MRI is both acceptably high and similar to previ

260 raphy (BI-RADS 4/5) underwent combined (18)F-FDG PET/MRI of the breast at 3T with dynamic contrast-en

261 ty of the tumor tissue was assessed by (18)F-FDG PET/MRI once after PRRT.

262 Of 100 operations, preoperative F-FDG PET/CT showed additional lesions compared to anatomi

263 n the use of (18)F-fluorodeoxyglucose ((18)F-FDG) PET in the assessment of diffuse large B-cell lymph

264 for (18)F-labeled fluorodeoxyglucose ((18)F-FDG) PET, 0.64 and 0.83 for single-photon emission compu

265 osition, and (18)F-fluorodeoxyglucose ((18)F-FDG) PET, which assesses glucose metabolism, provide val

266 (18)F-FDG-PET analyses of tumors demonstrate that Glut1 and Gl

267 a strong positive correlation between (18)F-FDG-PET and lactate production, while pO(2) was inversel

268 er sequences, in which amyloid-PET and (18)F-FDG-PET are placed at different positions in the order o

269 yglucose positron emission tomography ((18)F-FDG-PET).

270 Herein, we report a (18)F-FDG-PET/CT-based deep learning model, which demonstrates

271 dditional lesions detected on preoperative F-FDG-PET/CT imaging have an impact on the surgical approa

272 tumor with (18)F-fluorodeoxyglucose ([(18)F]FDG) PET may assist in predicting treatment response in

273 and could not explain the failure of [(18)F]FDG-PET to detect treatment response.

274 d glucose uptake (GU) from whole-body [(18)F]FDG-PET/MR images.

275 Twelve subjects underwent whole-body [(18)F]FDG-PET/MRI during hyperinsulinemic-euglycemic clamp.

276 easured with fluorine 18 fluorodeoxyglucose (FDG) PET.

277 tigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac MRI.

278 ve study, 110 whole-body fluorodeoxyglucose (FDG) PET/CT studies acquired in 107 patients (mean age +

279 ound Fluorine 18 ((18)F)-fluorodeoxyglucose (FDG) PET/CT is a routine tool for staging patients with

280 iance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characte

281 , we aimed to identify a fluorodeoxyglucose (FDG)-PET based imaging marker of cognitive resilience.

282 6 of 56 participants; 95% CI: 54%, 100%) for FDG PET/MRI.

283 he maximum SUV (SUV(max)) is measurable from FDG PET/CT with a within-subject coefficient of variatio

284 e predictive and prognostic value of interim FDG PET (iPET) in evaluating early response to immunoche

285 olling for other risk factors for mortality, FDG-PET/CT performance among all patients was independen

286 Greater lung TGA on FDG PET-CT was associated with worse lung function and r

287 PET.Keywords: digital PET; conventional PET; FDG PET; lesion detection; cancer imaging.

288 Global PIB ratio, FDG-PET ratio and cortical thickness from Alzheimer's di

289 Recent studies suggest that FDG-PET/CT could help discriminate between active and re

290 s to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to

291 llin susceptibility and survival duration to FDG-PET/CT.

292 yglucose-based positron emission tomography (FDG-PET) as a contrast mechanism.

293 rodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (in

294 rodeoxyglucose positron emission tomography (FDG-PET) response criteria in non-small-cell lung cancer

295 rodeoxyglucose positron emission tomography (FDG-PET) scans.

296 These results suggest that pre-treatment FDG-PET features may be useful to detect patients who do

297 oup) were prospectively recruited to undergo FDG-PET/CT 7-14 days after diagnosis.

298 p of patients with SAB who had not undergone FDG-PET/CT, matched by age, Charlson score, methicillin

299 with 151 separate episodes of SAB underwent FDG-PET/CT and were compared to 150 matched patients wit

300 y among small nodes, when used together with FDG-PET.